Bionomics

Bionomics ROA

Delisted

The Return on Assets (ROA) of Bionomics (BNO.AX) as of Sep 27, 2026 is -33.32 %. In the previous year, Return on Assets (ROA) was -16.03 % — a change of 107.87% (lower).

ROA

-33.32 %

YoY

107.87%

Last updated:

In 2026, Bionomics's return on assets (ROA) was -33.32 %, a 107.87% increase from the -16.03 % ROA in the previous year.

The Bionomics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-24.52 AUD
Jan 1, 2016
-18.48 AUD
Jan 1, 2017
-8.03 AUD
Jan 1, 2018
-38.55 AUD
Jan 1, 2019
-19.31 AUD
Jan 1, 2020
-20.65 AUD
Jan 1, 2021
-16.03 AUD
Jan 1, 2022
-33.32 AUD
The Bionomics ROA history
YEARROAYoY
-33.32 %+107.87%
-16.03 %-22.40%
-20.65 %+6.97%
-19.31 %-49.91%
-38.55 %+380.24%
-8.03 %-56.55%
-18.48 %-24.65%
-24.52 %-596.92%
4.93 %—
Access this data via the Eulerpool API
Get Free API Key

Bionomics Stock analysis

What does Bionomics do? Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Bionomics's Return on Assets (ROA)

Bionomics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Bionomics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Bionomics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Bionomics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Bionomics stock

Return on Assets (ROA) of Bionomics is -33.32 % in 2026.

Return on Assets (ROA) of Bionomics changed from -16.03 % to -33.32 %, representing a 107.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Bionomics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Bionomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Bionomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bionomics